LONDON, May 5, 2016 /PRNewswire/ -- Renal cell carcinoma, also called renal adenocarcinoma, is a disease in which malignant or cancerous cells are found in the lining of tubules in the kidney. There are many factors, like smoking, hypertension, unhealthy eating habits and family history, which increase the risk of occurrence of renal cell carcinoma. Various tests, like ultrasound, urine analysis, intravenous pyelogram, CT scan, MRI and biopsy, are available now-a-days that can help in early diagnosis of this disease. The drugs which are used for the treatment of the renal cell carcinoma include the likes of Sutent, Votrient, Inlyta and Nexavar among others. The latest addition to this lot is Opdivo by Bristol-Myers Squibb. Moreover, there are many more drugs in various phases of clinical trials, which will help in the growth of this market.
According to the report "Global Renal Cell Carcinoma Drugs Market 2020", the renal cell carcinoma drugs market is anticipated to cross US$ 4 Billion by 2020. The report provides a detailed analysis of the market for these drugs. The report provides the current and forecasted market for renal cell carcinoma drugs.
Moreover, the report provides information and revenues of the major branded drugs in the market for this disease. The segmentation of renal cell carcinoma drugs market has been done in the report on the basis of different geographical regions. North America is accounted for the largest share of the renal cell carcinoma market. This high share was attributed to colossal patient pool, large number of commercially available drugs for the treatment of renal cell carcinoma, favourable healthcare insurance coverage, and impressive healthcare systems customized for the pharmaceutical sector. However, the Asia Pacific market is poised to witness the highest growth in coming years owing to improving healthcare facilities in the region coupled with rising patient pool.
It also highlights RCC drugs at various stages of clinical development. In addition, the report also provides insight about the major drivers and challenges, latest trends and developments, and strategic collaborations impacting the industry growth.
The later part of the report discusses some of the prominent players in the global renal cell carcinoma drug market. The market share analysis of these players is also provided in the report. Furthermore, a brief business overview of each player has been provided along with their business segments, product portfolios and recent developments. Moreover, analysis of their strengths and weaknesses has also been done. Overall, the report will prove as a complete source of knowledge and analysis for clients and potential investors.
Download the full report: https://www.reportbuyer.com/product/3621490/
Reportbuyer is a leading industry intelligence solution that provides all market research reports from top publishers
For more information:
Research Advisor at Reportbuyer.com
Tel: +44 208 816 85 48
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/global-renal-cell-carcinoma-drugs-market-2020-300263647.html